Now hear this

How Frequency is restoring hearing with next-generation regenerative medicine

Most regenerative medicine companies are using stem cell therapies to replace and regrow damaged tissues, but development of stem cell therapies is complicated by manufacturing and regulatory challenges. Frequency Therapeutics Inc. is creating a next generation approach to regenerative medicine that uses small molecules to reactivate a patient’s dormant progenitor cells in vivo.

The newco emerged from stealth mode last week with the announcement of its new board of directors, which is headed by Chairman Marc Cohen, co-founder of Cobro Ventures, and includes serial entrepreneur and co-founder Robert Langer, David H. Koch Institute Professor at the Massachusetts Institute of Technology. The company has an undisclosed amount of financing from Cobro, and a group of angel and super angel investors.

Langer launched the company with Harvard University professor Jeffrey Karp in 2015, to develop a regenerative treatment for chronic

Read the full 1366 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers